Clinical trials: Amyloid Cardiomyopathy
ATTR-CM, TTR-CM
Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy
Open-label Safety and Efficacy Evaluation of Fx-1006a in Patients with V122i Or Wild-type Transthyretin (ttr) Amyloid Cardiomyopathy.
- Trial name
- NCT00935012
- Testing
- tafamidis
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Pfizer
Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP), Transthyretin Cardiomyopathy (TTR-CM)
Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers
This study is an online (web-based) or paper-based survey for patients with transthyretin familial amyloidosis polyneuropathy (TTR-FAP) and caregivers.
- Conditions
- Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP), Transthyretin Cardiomyopathy (TTR-CM), Familial Amyloid Cardiomyopathy, Senile Systemic Amyloidosis (SSA)
- Trial name
- NCT01604122
- Testing
- No drug
- Volunteers
- 1 people
- Sponsor
- Pfizer
Wild-type Transthyretin Amyloidosis
Prevalence of Wild Type ATTR
Prospective, observational, single-centre, non-interventional study aiming at reporting the prevalence of ATTRwt in patients with lumbar spinal stenosis (LSS).
- Trial name
- NCT03966105
- Testing
- HE and Congo red staining
- Where
- Switzerland
- Volunteers
- 94 people
- Sponsor
- Oncology Institute of Southern Switzerland
Mitral Regurgitation, ATTR-Cardiomyopathy
Edge-to-edge Mitral Valve Repair in ATTR-CM
No previous study has evaluated the effectiveness of transcatheter edge-to-edge mitral valve repair (TEER) in patients with ATTR-associated cardiomyopathy (ATTR-CM) and significant mitral regurgitation, as this specific patient…
- Conditions
- Mitral Regurgitation, ATTR-Cardiomyopathy, Edge-to-Edge Mitral Valve Repair
- Trial name
- MILLENNIAL (NCT06075823)
- Testing
- TEER, Optimal Medical Therapy
- Where
- 10 sites in Austria, Germany and 1 more
- Volunteers
- 106 people
- Sponsor
- Medical University of Vienna
Cardiac Amyloidosis
Cardiac Amyloidosis : Diagnostic Using Red Flag Signals
Cardiac amyloidosis is an increasingly contributor of degenerative cardiac diseases. However, its frequency remains underestimated, and diagnosis is often realized at late stages of the disease.
- Trial name
- TEAM Red Flags (NCT04459169)
- Testing
- diagnostic algorithm
- Where
- 3 sites in Guadeloupe, Martinique
- Volunteers
- 424 people
- Sponsor
- University Hospital Center of Martinique
Amyloid Cardiomyopathy, Transthyretin Amyloid Cardiomyopathy
Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis
The goal of this study is to develop an algorithm using artificial intelligence (AI) to assist identification of potential ATTR-CM cases using routine transthoracic echocardiography.
- Conditions
- Amyloid Cardiomyopathy, Transthyretin Amyloid Cardiomyopathy, Transthyretin Cardiac Amyloidosis
- Trial name
- AI-ATTR-ECHO (NCT06328075)
- Testing
- non interventional study
- Where
- France
- Volunteers
- 15,000 people
- Sponsor
- Algalarrondo Vincent
Cardiac Amyloidosis
Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.
To estimate distribution's parameters of 18F-Flutemetamol (Vizamyl®) fixation on myocardium for patients with amyloid cardiac injuries.
- Trial name
- AMYLCAR (NCT03232632)
- Testing
- PET with 18 F-Flutemetamol
- Where
- France
- Volunteers
- 7 people
- Sponsor
- University Hospital, Toulouse
Heart Failure
Heart Failure: Don't Forget the Role of Amyloidosis
Heart failure is defined as the inability of the heart to provide sufficient output to meet the needs of the body. It can occur in the course of a myocardial infarction, angina pectoris, hypertension, etc.
- Trial name
- TEAM-HF (NCT05501847)
- Testing
- Patient with no ventricular hypertrophy
- Where
- 2 sites in Guadeloupe, Martinique
- Volunteers
- 446 people
- Sponsor
- University Hospital Center of Martinique
Transthyretin Amyloidosis
The Regional Scintigraphic DPD Uptake in Cardiac Transthyretin Amyloidosis.
Cardiac transthyretin (ATTR) amyloidosis is an infiltrative cardiomyopathy with an inexorably progressive clinical course and poor prognosis.
- Trial name
- AMYLOIDOZA (NCT05814380)
- Testing
- 99mTc-DPD scintigraphy, Collection of blood samples and echocardiography
- Where
- Poland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Katarzyna Holcman
Amyloidosis, Amyloid Cardiomyopathy
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
Phase 3 efficacy and safety study to evaluate acoramidis (AG10) HCl 800 mg administered orally twice a day compared to placebo in subjects with symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
- Conditions
- Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
- Trial name
- ATTRibute-CM (NCT03860935)
- Testing
- acoramidis
- Where
- 104 sites in United States, Australia and 16 more
- Volunteers
- 632 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Polyneuropathies, Wild Type ATTR Amyloidosis
Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy
To evaluate the efficacy and safety of patisiran in patients with wtATTR amyloidosis and symptomatic polyneuropathy by evaluating the effect on neurologic impairment and quality of life.
- Conditions
- Polyneuropathies, Wild Type ATTR Amyloidosis, Wild-Type Transthyretin-Related (ATTR)Amyloidosis, Wild-Type Transthyretin Cardiac Amyloidosis
- Trial name
- NCT05023889
- Testing
- patisiran
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Austin Neuromuscular Center
Cardiac Amyloidosis, Spinal Stenosis
Prevalence of Cardiac Amyloidosis Among Patients With a History of Lumbar Spinal Stenosis.
The study investigates the prevalence of cardiac amyloidosis among patients with a history of lumbar spinal stenosis within the last ten years in the region of central Denmark.
- Trial name
- CASS-I (NCT05701410)
- Testing
- DPD scintigraphy
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Steen Hvitfeldt Poulsen
Cardiac Amyloidosis
PET/MRI Evaluation of Cardiac Amyloid
Cardiac amyloidosis is a disorder characterized by the deposition of abnormal proteins called amyloid in the heart tissue. This makes it difficult for the heart to function properly.
- Trial name
- NCT03119558
- Testing
- 18F-Florbetaben (Neuraceq®) PET/MRI
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Stanford University
Transthyretin Amyloidosis
New Biomarkers and Plasma Prothrombotic Potential in Cardiac Transthyretin Amyloidosis
The development of cardiac amyloidosis is caused by the deposition of misfolded, insoluble proteins in the extracellular matrix of tissues.
- Trial name
- NCT06345235
- Testing
- blood test
- Where
- Poland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- John Paul II Hospital, Krakow
Amyloid, Amyloidosis
Screening for Systemic Amyloidosis Via the Ligamentum Flavum
The investigators will prospectively evaluate for the presence of amyloid deposits in ligamentum flavum (yellow ligament) tissue samples obtained from patients undergoing spinal stenosis surgery.
- Conditions
- Amyloid, Amyloidosis, Spinal Stenosis, Transthyretin Amyloidosis
- Trial name
- ALF (NCT03923920)
- Testing
- Biopsy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- The Cleveland Clinic
Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
The purpose of this study is to: Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients Characterize the safety and effectiveness of patisiran and…
- Trial name
- ConTTRibute (NCT04561518)
- Where
- 40 sites in United States, Brazil and 10 more
- Volunteers
- 1,500 people
- Sponsor
- Alnylam Pharmaceuticals
Hereditary Transthyretin Amyloidosis With Polyneuropthy
A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN
The objective of the study was to characterize adverse events (AEs) occurring within one day of TEGSEDI administration to adult participants with hATTR-PN overall and in individual participants with respect to time course of AE…
- Trial name
- NCT04306510
- Testing
- TEGSEDI
- Where
- 2 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- Akcea Therapeutics
Amyloidosis
A PILOT Study on LSGB vs EMB in the Diagnosis of Cardiac Transthyretin Amyloidosis
Transthyretin (TTR) is a plasma protein mainly synthesized in the liver, recognized as a transporter of thyroxine and retinol-binding protein.
- Trial name
- NCT05375279
- Testing
- Lip Salivary Gland Biopsy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Unity Health Toronto
Transthyretin Amyloid Cardiopathy
ATTR-CM: A Multi-country, Non-interventional Disease Registry
This study is a multi-center, non-interventional, disease registry to characterize the natural history of ATTR-CM and treatment patterns in clinically diagnosed ATTR-CM patients.
- Trial name
- NCT06651073
- Testing
- Observational
- Where
- 17 sites in Hong Kong, Malaysia and 1 more
- Volunteers
- 350 people
- Sponsor
- Pfizer
Transthyretin Amyloid Cardiomyopathy ("ATTR-CM")
A Prospective Study to Assess the Utility of CA-4F in a Canadian Cardiology Setting
This study will assess whether CA-4F can improve diagnosis of ATTR-CM in a community cardiology setting when used to screen electronic medical record data for patients suitable for follow-up investigations.
- Trial name
- NCT05210010
- Testing
- CA-4F
- Where
- 3 sites in Canada
- Volunteers
- 8 people
- Sponsor
- Ensho Health Intelligent Systems Inc.